Paula Roberson
Concepts (402)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 6 | 2019 | 492 | 0.850 |
Why?
| Fluorocarbons | 3 | 2019 | 45 | 0.610 |
Why?
| Cerebral Angiography | 4 | 2012 | 97 | 0.550 |
Why?
| Cognition Disorders | 6 | 2011 | 218 | 0.440 |
Why?
| Vision Tests | 1 | 2011 | 13 | 0.400 |
Why?
| Mydriatics | 1 | 2011 | 12 | 0.390 |
Why?
| Apnea | 1 | 2011 | 18 | 0.390 |
Why?
| Retinopathy of Prematurity | 1 | 2011 | 13 | 0.390 |
Why?
| Tissue Plasminogen Activator | 5 | 2022 | 109 | 0.380 |
Why?
| Osteoblasts | 7 | 2014 | 450 | 0.380 |
Why?
| Disease Models, Animal | 3 | 2012 | 1455 | 0.380 |
Why?
| Bone and Bones | 6 | 2013 | 469 | 0.360 |
Why?
| Patient Care Planning | 2 | 2010 | 67 | 0.360 |
Why?
| Energy Intake | 4 | 2016 | 170 | 0.350 |
Why?
| Apoptosis | 8 | 2014 | 1101 | 0.340 |
Why?
| Pleural Effusion | 2 | 2022 | 38 | 0.330 |
Why?
| Aged | 23 | 2021 | 9310 | 0.330 |
Why?
| Aging | 5 | 2014 | 687 | 0.330 |
Why?
| Alzheimer Disease | 4 | 2018 | 324 | 0.310 |
Why?
| Warts | 2 | 2005 | 13 | 0.310 |
Why?
| Microbubbles | 4 | 2011 | 25 | 0.310 |
Why?
| Antigens, Fungal | 2 | 2005 | 24 | 0.310 |
Why?
| Antigens, Viral | 2 | 2005 | 44 | 0.310 |
Why?
| Nursing Research | 2 | 2009 | 42 | 0.300 |
Why?
| Parathyroid Hormone | 4 | 2010 | 147 | 0.290 |
Why?
| Apathy | 2 | 2018 | 39 | 0.290 |
Why?
| Bone Density | 8 | 2014 | 379 | 0.280 |
Why?
| Activities of Daily Living | 6 | 2017 | 174 | 0.270 |
Why?
| Immunotherapy | 2 | 2005 | 238 | 0.260 |
Why?
| Prospective Studies | 13 | 2022 | 2364 | 0.260 |
Why?
| Veterans | 3 | 2023 | 555 | 0.260 |
Why?
| Oxidative Stress | 5 | 2013 | 770 | 0.260 |
Why?
| Tai Ji | 3 | 2011 | 22 | 0.260 |
Why?
| Hospitalization | 2 | 2016 | 652 | 0.260 |
Why?
| Trichophyton | 1 | 2005 | 3 | 0.260 |
Why?
| Female | 36 | 2021 | 26472 | 0.260 |
Why?
| Mumps virus | 1 | 2005 | 12 | 0.250 |
Why?
| Patient-Centered Care | 1 | 2007 | 129 | 0.250 |
Why?
| Behavior Therapy | 1 | 2007 | 181 | 0.250 |
Why?
| Osteocytes | 3 | 2014 | 207 | 0.250 |
Why?
| Candida | 1 | 2005 | 60 | 0.250 |
Why?
| Male | 33 | 2019 | 25241 | 0.250 |
Why?
| Ultrasonic Therapy | 3 | 2011 | 34 | 0.250 |
Why?
| Rabbits | 4 | 2012 | 370 | 0.240 |
Why?
| Nutrition Assessment | 3 | 2016 | 63 | 0.240 |
Why?
| Mortality | 4 | 2007 | 99 | 0.240 |
Why?
| Brain Ischemia | 2 | 2019 | 161 | 0.240 |
Why?
| Glucocorticoids | 3 | 2011 | 219 | 0.240 |
Why?
| Geriatric Assessment | 7 | 2012 | 112 | 0.230 |
Why?
| Health Promotion | 1 | 2007 | 271 | 0.230 |
Why?
| Osteogenesis | 6 | 2013 | 352 | 0.230 |
Why?
| Patient Education as Topic | 1 | 2007 | 302 | 0.230 |
Why?
| Thrombolytic Therapy | 3 | 2022 | 110 | 0.230 |
Why?
| Body Weight | 2 | 2012 | 513 | 0.230 |
Why?
| Humans | 43 | 2023 | 49974 | 0.220 |
Why?
| Protein-Energy Malnutrition | 1 | 2002 | 19 | 0.220 |
Why?
| Severity of Illness Index | 7 | 2017 | 945 | 0.210 |
Why?
| Empyema, Pleural | 1 | 2022 | 12 | 0.210 |
Why?
| Fibrinolytic Agents | 3 | 2022 | 124 | 0.200 |
Why?
| Pilot Projects | 6 | 2018 | 699 | 0.200 |
Why?
| Exercise Therapy | 2 | 2017 | 98 | 0.200 |
Why?
| Frail Elderly | 3 | 2007 | 32 | 0.200 |
Why?
| Animals | 19 | 2014 | 13187 | 0.200 |
Why?
| Nursing Evaluation Research | 3 | 2010 | 38 | 0.200 |
Why?
| Academic Medical Centers | 2 | 2013 | 144 | 0.190 |
Why?
| Inflammation | 3 | 2012 | 604 | 0.190 |
Why?
| Estrogen Receptor alpha | 2 | 2013 | 89 | 0.190 |
Why?
| Dermatology | 1 | 2021 | 49 | 0.180 |
Why?
| Cerebral Hemorrhage | 2 | 2011 | 104 | 0.180 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2021 | 186 | 0.170 |
Why?
| Coronary Artery Disease | 1 | 2002 | 274 | 0.160 |
Why?
| Double-Blind Method | 6 | 2019 | 681 | 0.160 |
Why?
| Cannabis | 1 | 2021 | 145 | 0.160 |
Why?
| Treatment Outcome | 9 | 2019 | 5141 | 0.160 |
Why?
| Neuroprotective Agents | 1 | 2019 | 105 | 0.160 |
Why?
| Patient Discharge | 4 | 2023 | 320 | 0.160 |
Why?
| Cognition | 3 | 2018 | 338 | 0.150 |
Why?
| Research Design | 3 | 2010 | 344 | 0.150 |
Why?
| Aged, 80 and over | 11 | 2017 | 3129 | 0.150 |
Why?
| Rehabilitation Centers | 3 | 2012 | 34 | 0.150 |
Why?
| Osteoarthritis, Knee | 2 | 2009 | 88 | 0.150 |
Why?
| Weight Gain | 2 | 2012 | 240 | 0.150 |
Why?
| Weight Loss | 2 | 2012 | 237 | 0.150 |
Why?
| Nutritional Status | 4 | 2012 | 141 | 0.140 |
Why?
| Sensation Disorders | 1 | 2017 | 11 | 0.140 |
Why?
| Transcranial Magnetic Stimulation | 1 | 2018 | 70 | 0.140 |
Why?
| Bone Remodeling | 4 | 2014 | 150 | 0.140 |
Why?
| Methylphenidate | 1 | 2017 | 75 | 0.140 |
Why?
| Chest Tubes | 1 | 2016 | 21 | 0.140 |
Why?
| Recovery of Function | 2 | 2019 | 188 | 0.140 |
Why?
| Pandemics | 1 | 2021 | 559 | 0.140 |
Why?
| Arkansas | 6 | 2019 | 1977 | 0.140 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2013 | 477 | 0.140 |
Why?
| Postural Balance | 1 | 2017 | 56 | 0.140 |
Why?
| Health Status | 2 | 2011 | 298 | 0.140 |
Why?
| Fear | 1 | 2017 | 82 | 0.130 |
Why?
| Nursing Homes | 2 | 2009 | 114 | 0.130 |
Why?
| Nursing Assessment | 4 | 2010 | 54 | 0.130 |
Why?
| Internship and Residency | 1 | 2021 | 443 | 0.130 |
Why?
| Ultrasonography, Interventional | 1 | 2016 | 136 | 0.130 |
Why?
| Pneumonia | 1 | 2016 | 118 | 0.130 |
Why?
| Accidental Falls | 1 | 2017 | 98 | 0.130 |
Why?
| Heart Defects, Congenital | 1 | 2021 | 595 | 0.130 |
Why?
| Central Nervous System Stimulants | 1 | 2017 | 213 | 0.120 |
Why?
| C-Reactive Protein | 3 | 2012 | 142 | 0.120 |
Why?
| Osteoclasts | 4 | 2013 | 425 | 0.120 |
Why?
| Mice | 11 | 2014 | 5739 | 0.120 |
Why?
| Brain | 2 | 2013 | 1328 | 0.120 |
Why?
| Prednisolone | 2 | 2011 | 55 | 0.120 |
Why?
| Cerebrovascular Circulation | 2 | 2013 | 132 | 0.120 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 194 | 0.120 |
Why?
| Serum Albumin | 3 | 2012 | 58 | 0.110 |
Why?
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2014 | 17 | 0.110 |
Why?
| bcl-2-Associated X Protein | 1 | 2014 | 56 | 0.110 |
Why?
| Biostatistics | 1 | 2013 | 5 | 0.110 |
Why?
| Personnel Management | 1 | 2013 | 12 | 0.110 |
Why?
| Hospitals, Veterans | 4 | 2008 | 110 | 0.110 |
Why?
| Time Factors | 7 | 2019 | 2903 | 0.110 |
Why?
| Hospital Units | 1 | 2012 | 9 | 0.110 |
Why?
| Vasodilation | 1 | 2013 | 96 | 0.110 |
Why?
| Physical Endurance | 1 | 2012 | 30 | 0.110 |
Why?
| Random Allocation | 2 | 2011 | 281 | 0.110 |
Why?
| Intracranial Embolism | 1 | 2012 | 27 | 0.110 |
Why?
| Prealbumin | 2 | 2012 | 21 | 0.110 |
Why?
| Forkhead Transcription Factors | 1 | 2013 | 112 | 0.110 |
Why?
| Wnt Signaling Pathway | 1 | 2013 | 92 | 0.110 |
Why?
| Leg | 1 | 2012 | 122 | 0.100 |
Why?
| Data Interpretation, Statistical | 2 | 2010 | 158 | 0.100 |
Why?
| Health Services Research | 1 | 2013 | 150 | 0.100 |
Why?
| Cell Nucleus | 1 | 2013 | 183 | 0.100 |
Why?
| Edema | 1 | 2012 | 67 | 0.100 |
Why?
| Hypoglycemic Agents | 1 | 2013 | 168 | 0.100 |
Why?
| Emulsions | 1 | 2011 | 24 | 0.100 |
Why?
| Intensive Care, Neonatal | 1 | 2011 | 23 | 0.100 |
Why?
| Malnutrition | 1 | 2012 | 87 | 0.100 |
Why?
| Osteoprotegerin | 1 | 2011 | 52 | 0.100 |
Why?
| Cell Adhesion Molecules | 1 | 2011 | 88 | 0.100 |
Why?
| Insulin | 1 | 2013 | 457 | 0.100 |
Why?
| Chi-Square Distribution | 1 | 2011 | 280 | 0.090 |
Why?
| Estrogens | 2 | 2010 | 227 | 0.090 |
Why?
| Sclerotherapy | 1 | 2011 | 45 | 0.090 |
Why?
| Face | 1 | 2011 | 60 | 0.090 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2009 | 549 | 0.090 |
Why?
| Muscle, Skeletal | 2 | 2007 | 750 | 0.090 |
Why?
| Middle Aged | 10 | 2019 | 12069 | 0.090 |
Why?
| Mice, Inbred C57BL | 6 | 2013 | 1816 | 0.090 |
Why?
| Genetic Techniques | 1 | 2010 | 14 | 0.090 |
Why?
| Case-Control Studies | 4 | 2021 | 1131 | 0.090 |
Why?
| Dietary Proteins | 1 | 2012 | 242 | 0.090 |
Why?
| Weight Lifting | 2 | 2007 | 29 | 0.090 |
Why?
| Statistics as Topic | 1 | 2010 | 88 | 0.090 |
Why?
| Sound | 1 | 2009 | 11 | 0.090 |
Why?
| Water | 1 | 2009 | 77 | 0.090 |
Why?
| Neovascularization, Physiologic | 1 | 2009 | 68 | 0.080 |
Why?
| Logistic Models | 2 | 2021 | 888 | 0.080 |
Why?
| Vascular Malformations | 1 | 2011 | 98 | 0.080 |
Why?
| Premature Birth | 1 | 2011 | 147 | 0.080 |
Why?
| Vascular Surgical Procedures | 1 | 2011 | 165 | 0.080 |
Why?
| Alendronate | 1 | 2009 | 23 | 0.080 |
Why?
| Pain | 2 | 2009 | 379 | 0.080 |
Why?
| Femur | 3 | 2014 | 133 | 0.080 |
Why?
| Multienzyme Complexes | 2 | 2010 | 34 | 0.080 |
Why?
| Periosteum | 1 | 2008 | 26 | 0.080 |
Why?
| Mitosis | 1 | 2008 | 91 | 0.080 |
Why?
| Nonverbal Communication | 1 | 2008 | 14 | 0.080 |
Why?
| Injections, Intralesional | 2 | 2005 | 31 | 0.080 |
Why?
| Verbal Behavior | 1 | 2008 | 35 | 0.080 |
Why?
| Osteoarthritis | 1 | 2008 | 62 | 0.080 |
Why?
| Nocturnal Myoclonus Syndrome | 1 | 2008 | 13 | 0.080 |
Why?
| Patient Selection | 1 | 2009 | 253 | 0.080 |
Why?
| Bone Density Conservation Agents | 1 | 2009 | 77 | 0.080 |
Why?
| Gonadal Steroid Hormones | 1 | 2007 | 42 | 0.070 |
Why?
| Child | 5 | 2022 | 6847 | 0.070 |
Why?
| Nursing Theory | 1 | 2007 | 5 | 0.070 |
Why?
| Independent Living | 2 | 2017 | 41 | 0.070 |
Why?
| Cell Differentiation | 1 | 2010 | 651 | 0.070 |
Why?
| Pain Measurement | 1 | 2008 | 240 | 0.070 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2007 | 21 | 0.070 |
Why?
| Psychological Theory | 1 | 2007 | 23 | 0.070 |
Why?
| Megestrol Acetate | 1 | 2007 | 17 | 0.070 |
Why?
| Cerebellum | 1 | 2008 | 135 | 0.070 |
Why?
| Cohort Studies | 3 | 2012 | 1422 | 0.070 |
Why?
| Radiology, Interventional | 1 | 2007 | 31 | 0.070 |
Why?
| Phosphorylation | 4 | 2010 | 535 | 0.070 |
Why?
| Cells, Cultured | 4 | 2013 | 1573 | 0.070 |
Why?
| Muscle Strength | 1 | 2007 | 124 | 0.070 |
Why?
| Hypoalbuminemia | 1 | 2005 | 4 | 0.060 |
Why?
| Transcription Factors | 2 | 2013 | 561 | 0.060 |
Why?
| Histocompatibility Antigens | 1 | 2005 | 6 | 0.060 |
Why?
| Adult | 6 | 2021 | 13236 | 0.060 |
Why?
| Evidence-Based Medicine | 1 | 2007 | 247 | 0.060 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 56 | 0.060 |
Why?
| Ethanol | 1 | 2008 | 340 | 0.060 |
Why?
| Interferon-alpha | 1 | 2005 | 47 | 0.060 |
Why?
| Testosterone | 1 | 2005 | 139 | 0.060 |
Why?
| Prognosis | 3 | 2005 | 1942 | 0.060 |
Why?
| Social Support | 1 | 2007 | 263 | 0.060 |
Why?
| Polysomnography | 3 | 2009 | 71 | 0.060 |
Why?
| Papillomaviridae | 1 | 2005 | 102 | 0.060 |
Why?
| Health Behavior | 1 | 2007 | 254 | 0.060 |
Why?
| Reactive Oxygen Species | 3 | 2013 | 408 | 0.060 |
Why?
| Intracranial Thrombosis | 1 | 2004 | 16 | 0.060 |
Why?
| Monocytes | 1 | 2005 | 131 | 0.060 |
Why?
| Cell Division | 1 | 2005 | 292 | 0.060 |
Why?
| Infant | 3 | 2021 | 3567 | 0.060 |
Why?
| Cytokines | 1 | 2007 | 612 | 0.060 |
Why?
| Walking | 2 | 2017 | 94 | 0.060 |
Why?
| Retrospective Studies | 3 | 2022 | 6108 | 0.060 |
Why?
| Mental Status Schedule | 2 | 2017 | 16 | 0.060 |
Why?
| Infant, Newborn | 1 | 2011 | 2772 | 0.060 |
Why?
| Recombinant Proteins | 1 | 2005 | 486 | 0.060 |
Why?
| Antiviral Agents | 1 | 2005 | 173 | 0.060 |
Why?
| Pediatrics | 1 | 2007 | 279 | 0.060 |
Why?
| Young Adult | 3 | 2022 | 3958 | 0.060 |
Why?
| Cysteine Endopeptidases | 1 | 2003 | 67 | 0.060 |
Why?
| Agricultural Workers' Diseases | 1 | 2003 | 6 | 0.060 |
Why?
| Aircraft | 1 | 2003 | 9 | 0.060 |
Why?
| Albumins | 1 | 2003 | 31 | 0.050 |
Why?
| Pesticides | 1 | 2003 | 18 | 0.050 |
Why?
| Nutrition Disorders | 1 | 2002 | 14 | 0.050 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2004 | 172 | 0.050 |
Why?
| Arteriovenous Shunt, Surgical | 1 | 2003 | 29 | 0.050 |
Why?
| Diet Records | 2 | 2016 | 17 | 0.050 |
Why?
| Aftercare | 1 | 2023 | 75 | 0.050 |
Why?
| Atrophy | 2 | 2013 | 38 | 0.050 |
Why?
| Skin Diseases | 1 | 2003 | 112 | 0.050 |
Why?
| Follow-Up Studies | 3 | 2017 | 2182 | 0.050 |
Why?
| Personnel Selection | 1 | 2021 | 24 | 0.050 |
Why?
| Contrast Media | 1 | 2003 | 184 | 0.050 |
Why?
| Occupational Exposure | 1 | 2003 | 122 | 0.050 |
Why?
| Signal Transduction | 2 | 2010 | 1618 | 0.050 |
Why?
| Videoconferencing | 1 | 2021 | 37 | 0.050 |
Why?
| Exercise | 1 | 2005 | 495 | 0.050 |
Why?
| Neoplasm Proteins | 1 | 2003 | 322 | 0.050 |
Why?
| Schools, Medical | 1 | 2021 | 69 | 0.050 |
Why?
| Risk Factors | 3 | 2021 | 3613 | 0.050 |
Why?
| Shc Signaling Adaptor Proteins | 2 | 2010 | 20 | 0.050 |
Why?
| Ovariectomy | 2 | 2013 | 119 | 0.040 |
Why?
| Thrombosis | 1 | 2003 | 248 | 0.040 |
Why?
| Stem Cells | 2 | 2013 | 171 | 0.040 |
Why?
| Maximum Tolerated Dose | 1 | 2019 | 37 | 0.040 |
Why?
| Neuropsychological Tests | 2 | 2013 | 353 | 0.040 |
Why?
| Administration, Intravenous | 1 | 2019 | 69 | 0.040 |
Why?
| Asthma | 1 | 2003 | 281 | 0.040 |
Why?
| Disability Evaluation | 1 | 2019 | 87 | 0.040 |
Why?
| Drug Administration Schedule | 1 | 2019 | 376 | 0.040 |
Why?
| Child, Preschool | 3 | 2016 | 3871 | 0.040 |
Why?
| Diet | 2 | 2016 | 566 | 0.040 |
Why?
| Ultrasonography, Doppler, Transcranial | 2 | 2011 | 25 | 0.040 |
Why?
| Cell Line | 2 | 2011 | 1000 | 0.040 |
Why?
| Cell Proliferation | 2 | 2013 | 1007 | 0.040 |
Why?
| Calcium | 2 | 2014 | 396 | 0.040 |
Why?
| Smoking | 1 | 2021 | 511 | 0.040 |
Why?
| Hypertension | 1 | 2002 | 533 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2018 | 224 | 0.040 |
Why?
| Executive Function | 1 | 2018 | 76 | 0.040 |
Why?
| Antioxidants | 2 | 2010 | 249 | 0.040 |
Why?
| Food Service, Hospital | 1 | 2016 | 3 | 0.040 |
Why?
| Risk Assessment | 1 | 2021 | 1259 | 0.040 |
Why?
| Models, Genetic | 2 | 2010 | 170 | 0.030 |
Why?
| Photography | 1 | 2016 | 32 | 0.030 |
Why?
| Video Recording | 1 | 2017 | 79 | 0.030 |
Why?
| Length of Stay | 2 | 2011 | 619 | 0.030 |
Why?
| Drainage | 1 | 2016 | 78 | 0.030 |
Why?
| Meals | 1 | 2016 | 57 | 0.030 |
Why?
| Ultrasonography | 2 | 2011 | 436 | 0.030 |
Why?
| Blotting, Western | 2 | 2010 | 601 | 0.030 |
Why?
| Transcription, Genetic | 2 | 2010 | 369 | 0.030 |
Why?
| Adolescent | 3 | 2016 | 6356 | 0.030 |
Why?
| Caregivers | 1 | 2017 | 208 | 0.030 |
Why?
| United States | 2 | 2021 | 4860 | 0.030 |
Why?
| Inpatients | 1 | 2016 | 190 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2016 | 637 | 0.030 |
Why?
| Magnetic Resonance Imaging | 2 | 2011 | 1537 | 0.030 |
Why?
| Porosity | 1 | 2014 | 30 | 0.030 |
Why?
| Proportional Hazards Models | 2 | 2007 | 402 | 0.030 |
Why?
| Pregnancy | 1 | 2021 | 2607 | 0.030 |
Why?
| APACHE | 2 | 2004 | 23 | 0.030 |
Why?
| Administration, Intranasal | 1 | 2013 | 28 | 0.030 |
Why?
| Mice, 129 Strain | 1 | 2013 | 38 | 0.030 |
Why?
| Gene Knockout Techniques | 1 | 2013 | 40 | 0.030 |
Why?
| Cross-Sectional Studies | 2 | 2009 | 1557 | 0.030 |
Why?
| Magnetic Resonance Angiography | 1 | 2013 | 77 | 0.030 |
Why?
| Adipogenesis | 1 | 2013 | 51 | 0.030 |
Why?
| Intermediate Care Facilities | 1 | 2012 | 4 | 0.030 |
Why?
| Professional Competence | 1 | 2013 | 41 | 0.030 |
Why?
| Memory | 1 | 2013 | 116 | 0.030 |
Why?
| Models, Biological | 2 | 2008 | 727 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2016 | 1193 | 0.030 |
Why?
| Swine | 2 | 2004 | 393 | 0.030 |
Why?
| Regional Blood Flow | 1 | 2012 | 108 | 0.030 |
Why?
| Professional Role | 1 | 2013 | 76 | 0.030 |
Why?
| Homeostasis | 1 | 2014 | 200 | 0.030 |
Why?
| Organ Size | 1 | 2013 | 226 | 0.030 |
Why?
| Depression | 1 | 2017 | 568 | 0.030 |
Why?
| Uterus | 1 | 2013 | 94 | 0.030 |
Why?
| Spine | 1 | 2013 | 94 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2013 | 166 | 0.030 |
Why?
| Adiposity | 1 | 2013 | 127 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2013 | 555 | 0.020 |
Why?
| Body Mass Index | 2 | 2007 | 652 | 0.020 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2011 | 20 | 0.020 |
Why?
| Estradiol | 1 | 2013 | 225 | 0.020 |
Why?
| Immunoenzyme Techniques | 1 | 2011 | 143 | 0.020 |
Why?
| Bone Marrow | 1 | 2013 | 362 | 0.020 |
Why?
| Interleukin-6 | 1 | 2012 | 264 | 0.020 |
Why?
| Arthritis | 1 | 2011 | 42 | 0.020 |
Why?
| Arachidonate 12-Lipoxygenase | 1 | 2010 | 13 | 0.020 |
Why?
| Arachidonate 15-Lipoxygenase | 1 | 2010 | 13 | 0.020 |
Why?
| Blood Loss, Surgical | 1 | 2011 | 72 | 0.020 |
Why?
| Physical Fitness | 1 | 2011 | 54 | 0.020 |
Why?
| Veins | 1 | 2011 | 71 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2012 | 388 | 0.020 |
Why?
| Smad1 Protein | 1 | 2010 | 5 | 0.020 |
Why?
| Phenotype | 1 | 2013 | 729 | 0.020 |
Why?
| Gene Knock-In Techniques | 1 | 2010 | 22 | 0.020 |
Why?
| Glutathione Reductase | 1 | 2010 | 14 | 0.020 |
Why?
| Models, Nursing | 1 | 2010 | 16 | 0.020 |
Why?
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2009 | 12 | 0.020 |
Why?
| Wnt Proteins | 1 | 2010 | 100 | 0.020 |
Why?
| False Positive Reactions | 1 | 2010 | 63 | 0.020 |
Why?
| Bone Morphogenetic Protein 2 | 1 | 2010 | 46 | 0.020 |
Why?
| Preoperative Care | 1 | 2011 | 164 | 0.020 |
Why?
| Assisted Living Facilities | 1 | 2009 | 11 | 0.020 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 83 | 0.020 |
Why?
| Nursing Staff | 1 | 2009 | 15 | 0.020 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 56 | 0.020 |
Why?
| Analysis of Variance | 1 | 2011 | 562 | 0.020 |
Why?
| Enzyme Activation | 1 | 2010 | 276 | 0.020 |
Why?
| Southeastern United States | 1 | 2009 | 45 | 0.020 |
Why?
| Actigraphy | 1 | 2009 | 23 | 0.020 |
Why?
| Stress, Mechanical | 1 | 2009 | 88 | 0.020 |
Why?
| Databases, Genetic | 1 | 2010 | 88 | 0.020 |
Why?
| Multicenter Studies as Topic | 1 | 2009 | 84 | 0.020 |
Why?
| Acid Phosphatase | 1 | 2009 | 11 | 0.020 |
Why?
| Research Subjects | 1 | 2009 | 50 | 0.020 |
Why?
| Program Development | 1 | 2010 | 166 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2009 | 201 | 0.020 |
Why?
| Thymidine Kinase | 1 | 2008 | 19 | 0.020 |
Why?
| Ganciclovir | 1 | 2008 | 24 | 0.020 |
Why?
| Data Collection | 1 | 2010 | 279 | 0.020 |
Why?
| Cell Count | 1 | 2008 | 147 | 0.020 |
Why?
| Isoenzymes | 1 | 2009 | 168 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 411 | 0.020 |
Why?
| Discriminant Analysis | 1 | 2008 | 27 | 0.020 |
Why?
| Program Evaluation | 1 | 2010 | 354 | 0.020 |
Why?
| Behavior | 1 | 2008 | 45 | 0.020 |
Why?
| Attitude to Health | 1 | 2009 | 192 | 0.020 |
Why?
| Mobility Limitation | 1 | 2008 | 21 | 0.020 |
Why?
| Postmenopause | 1 | 2009 | 100 | 0.020 |
Why?
| Linear Models | 1 | 2009 | 280 | 0.020 |
Why?
| Collagen Type I | 1 | 2008 | 89 | 0.020 |
Why?
| Matrix Metalloproteinases | 1 | 2008 | 48 | 0.020 |
Why?
| Observer Variation | 1 | 2008 | 130 | 0.020 |
Why?
| Feasibility Studies | 1 | 2009 | 375 | 0.020 |
Why?
| DNA Replication | 1 | 2008 | 150 | 0.020 |
Why?
| Electroencephalography | 1 | 2009 | 306 | 0.020 |
Why?
| Motivation | 1 | 2009 | 273 | 0.020 |
Why?
| Androgens | 1 | 2007 | 69 | 0.020 |
Why?
| Psychometrics | 1 | 2008 | 224 | 0.020 |
Why?
| Animals, Newborn | 1 | 2008 | 367 | 0.020 |
Why?
| Biopsy | 1 | 2009 | 584 | 0.020 |
Why?
| Algorithms | 1 | 2010 | 615 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2009 | 1376 | 0.020 |
Why?
| Gene Expression Profiling | 1 | 2010 | 1032 | 0.020 |
Why?
| Prevalence | 1 | 2008 | 944 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2007 | 903 | 0.020 |
Why?
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2004 | 32 | 0.010 |
Why?
| Injections, Intravenous | 1 | 2004 | 140 | 0.010 |
Why?
| Regression Analysis | 1 | 2005 | 395 | 0.010 |
Why?
| bcl-Associated Death Protein | 1 | 2003 | 9 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2008 | 1597 | 0.010 |
Why?
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2003 | 30 | 0.010 |
Why?
| Dactinomycin | 1 | 2003 | 22 | 0.010 |
Why?
| Culture Media, Conditioned | 1 | 2003 | 48 | 0.010 |
Why?
| Core Binding Factor Alpha 1 Subunit | 1 | 2003 | 44 | 0.010 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 34 | 0.010 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 2003 | 51 | 0.010 |
Why?
| Mumps | 1 | 2003 | 14 | 0.010 |
Why?
| Microspheres | 1 | 2003 | 25 | 0.010 |
Why?
| Spirometry | 1 | 2003 | 29 | 0.010 |
Why?
| Respiratory Function Tests | 1 | 2003 | 90 | 0.010 |
Why?
| HeLa Cells | 1 | 2003 | 250 | 0.010 |
Why?
| Dogs | 1 | 2003 | 182 | 0.010 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2003 | 114 | 0.010 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 129 | 0.010 |
Why?
| RNA | 1 | 2003 | 170 | 0.010 |
Why?
| Anthropometry | 1 | 2002 | 92 | 0.010 |
Why?
| Candidiasis | 1 | 2003 | 114 | 0.010 |
Why?
| Blood Vessel Prosthesis | 1 | 2003 | 85 | 0.010 |
Why?
| RANK Ligand | 1 | 2003 | 179 | 0.010 |
Why?
| Glucose | 1 | 2004 | 344 | 0.010 |
Why?
| Membrane Glycoproteins | 1 | 2003 | 240 | 0.010 |
Why?
| Kinetics | 1 | 2003 | 623 | 0.010 |
Why?
| Health Surveys | 1 | 2003 | 232 | 0.010 |
Why?
| Carrier Proteins | 1 | 2003 | 304 | 0.010 |
Why?
| Renal Dialysis | 1 | 2003 | 169 | 0.010 |
Why?
| Rats | 1 | 2008 | 3305 | 0.010 |
Why?
| Bone Resorption | 1 | 2003 | 304 | 0.010 |
Why?
| Survival Analysis | 1 | 2002 | 653 | 0.010 |
Why?
| RNA, Messenger | 1 | 2003 | 1105 | 0.010 |
Why?
| Postoperative Complications | 1 | 2003 | 984 | 0.010 |
Why?
|
|
Roberson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|